Dan Wang

Dr. Dan Wang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2024 in World Journal of Gastroenterology
Verified
Journal Article
Open access
QHQian-Jun He
Qian-Jun He
YLYi-Fei Li
Yi-Fei Li
LZLing-Tong Zhao
Ling-Tong Zhao
CLChun-Tong Lin
Chun-Tong Lin
CYChun-Yan Yu
Chun-Yan Yu
DWDan Wang
Dan Wang
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 25% of the world's population and has become a leading cause of chronic liver disease. In recent years, an increasing amount of data suggests that MASLD is associated with aging. As the population ages, age-related MASLD will become a major global health problem. Targeting an aging will become a new approach to the treatment of MASLD. This paper reviews the current studies on the role of aging-related factors and therapeutic targets in MASLD, including: Oxidative stress, autophagy, mitochondrial homeostasis, bile acid metabolism homeostasis, and dysbiosis. The aim is to identify effective therapeutic targets for age-related MASLD and its progression.

23 January 2024 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
SHSiqi He
Siqi He
WJWeijie Jiang
Weijie Jiang
BJBaoyi Jiang
Baoyi Jiang
CYChunyan Yu
Chunyan Yu
GZGuifang Zhao
Guifang Zhao
DWDan Wang
Dan Wang

12 June 2023 in Pharmacognosy Magazine
Verified
Journal Article
Open access
DWDan Wang
Dan Wang
DJDuochun Ji
Duochun Ji
DWDanni Wu
Danni Wu
LWLike Wang
Like Wang
CYChunyan Yu
Chunyan Yu
DWDan Wang
Dan Wang
Background: One of the key factors limiting the effectiveness of chemotherapy treatment for malignancies is multidrug resistance (MDR). The MDR phenotype is related to P-glycoprotein (P-gp) expression and function. The main triterpenoid saponins generated from Bupleurum chinense DC (BCDC), saikosaponin A (SSa), has been found to have anti-tumor potential. Saikosaponin B (SSb) has the potential for utility in combination with anticancer drugs as the secondary saikosaponins. Objective: In this study, we looked into the impact of SSa and SSb on doxorubicin (Dox)-resistant breast cancer cells and its underlying mechanisms. Materials and Methods: Dox-resistant breast cancer cells (MCF-7ADR) and MCF-7 cells were used in the study. The experimental cells were divided into a different concentration SSa administration group, a different concentration SSb administration group, and a control group, and the related biochemical parameters of MCF-7 and MCF-7ADR cells were detected. Results: We discovered that SSa and SSb both suppressed MCF-7 and MCF-7ADR cell proliferation in a dose-dependent manner. Additionally, SSa at 2.5 and 5.0 µg/mL and SSb at 3.0 and 7.0 µg/mL could significantly enhance the cytotoxicity of Dox and reverse MDR in MCF-7ADR cells. The combination of Dox and SSa or SSb induced obvious synergistic effects. SSa and SSb could increase the sensitivity of MCF-7ADR cells to Dox by decreasing P-gp expression, increasing intracellular accumulation, and delaying the drug efflux of rhodamine 123 (Rh123, a P-gp substrate). Additionally, SSa and SSb both induced G1-phase arrest in MCF-7ADR cells in the presence of Dox. Conclusion: According to the study, SSa and SSb may be novel MDR reversal medicines for breast cancer chemotherapy and have significant therapeutic significance for MDR during tumor therapy.